公开(公告)号：EP2049497A2

公开(公告)日：2009-04-22

申请号：EP06727141.1

申请日：2006-05-19

申请人： Astex Therapeutics Limited

发明人： CHESSARI, Gianni ,  CONGREVE, Miles Stuart ,  CALLAGHAN, Owen ,  COWAN, Suzanna Ruth ,  MURRAY, Christopher William ,  WOOLFORD, Alison, Jo-Anne ,  O'BRIEN, Michael Alistair ,  WOODHEAD, Andrew James

IPC分类号： C07D239/42 ,  C07D251/18 ,  C07D401/04 ,  C07D403/04

CPC分类号： C07D413/04 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D409/04

摘要： The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR3; R1 is a monocyclic or bicyclic carbocyclic or heterocyclic ring of 5 to 10 ring members of which up to two ring members may be heteroatoms selected from N, O and S and the remainder are carbon atoms, the carbocyclic or heterocyclic ring being optionally substituted by one or more substituent groups independently selected from R10; and R2, R3 and R10 are as defined in the claims.

公开(公告)号：EP1846395A1

公开(公告)日：2007-10-24

申请号：EP06709562.0

申请日：2006-01-20

申请人： Astex Therapeutics Limited

发明人： WYATT, Paul, Graham ,  BERDINI, Valerio ,  GILL, Adrian, Liam ,  TREWARTHA, Gary ,  WOODHEAD, Andrew James ,  NAVARRO, Eva Figueroa ,  O'BRIEN, Michael Alistair ,  PHILLIPS, Theresa Rachel

IPC分类号： C07D401/14 ,  A61K31/44 ,  A61P35/00 ,  A01N43/56

CPC分类号： C07D231/14 ,  C07D231/40 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/14

摘要： The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group R0; (e) a group R a; (f) a group Rlb; (g) a group Rlc; (h) a group Rld; and 0) 2,6-difluorophenylamino ; wherein R )0υ, r R> llaa, T Rj I1bD, T R) I1cC, r R> Iidα, r R»2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdkl or cdk2) and glycogen synthase kinase-3 activity.